Axi-Cel Superior to SOC in Elderly Patients with Diffuse Large B-Cell Lymphoma
Jason Westin, MD, FACP, leader, DLBCL research team, MD Anderson Cancer Center, discussed results from the ZUMA-7 trial at ASCO 2022.
Synthetic Binding Domain CAR T Therapy Yields 100% ORR in R/R Multiple Myeloma
69% of patients followed up for at least 1 year continue to have an ongoing response.
STRIVE-02: First-in-Human B7H3 CAR T-Cells for Pediatric Patients With Relapsed/Refractory Solid Tumors
Three of the 9 patients who received the infusion demonstrated best overall response of Stable Disease, and investigators determined dose level 2 to be the biologically effective dose.
Cilta-Cel Yields 100% ORR in Patients With Early Relapse of Multiple Myeloma
Niels van de Donk, MD, PhD, professor, Amsterdam University Medical Centers, discussed positive findings from cohort B of the CARTITUDE-2 study.
Early Bone Marrow MRD Status May Determine CAR-T Therapy Response in Myeloma
Regardless of bone marrow cellularity, bone marrow minimal residual disease (MRD) negativity at month 1 correlated with deep response and prolonged PFS.
Exploring New Paths for CAR T-Cell Therapy Research in Multiple Myeloma
Melissa Alsina, MD, gave a talk on novel CAR therapies, targets, and approaches at the 2022 ASCO meeting.
CAR T-Cell Therapy Directed at CLDN18.2 Effective in Gastric, Pancreatic Adenocarcinoma
Findings from the US-based study align with results from a phase 1b/2 study completed in China of CT041 in patients with gastric and gastroesophageal junction adenocarcinoma.
Kim A. Reiss Binder, MD, on the Potential of CAR Macrophages in Solid Tumors
The assistant professor of medicine at University of Pennsylvania Hospital stressed the importance of tumor sequencing.
POLARIS: OriCAR-017 Elicits 100% ORR in Patients With Relapsed/Refractory Multiple Myeloma
The phase 1, open-label, single-arm study demonstrated favorable safety and robust efficacy for the autologous GPRC5D-directed CAR-T cell therapy.
BCMA/CD19 Dual-Targeting CAR-T GC012F Continues to Display Durable Response for RRMM in Updated Results
Data were presented at ASCO 2021 and EHA 2021 for the initial 19 patients. Now, investigators are painting a fuller picture with an additional 9.
Novel Healthy Cell Sparing CAR T-cell Therapy Enters Clinical Studies for Solid Tumors
The BASECAMP-1 study is currently enrolling participants to explore the feasibility of manufacturing a novel CAR T-cell therapy with a target antigen activator and a HLA LOH-based blocker.
TCR Therapy Shows Anti-Tumor Activity in MRCLS
Higher-dose lymphodepleting regimens led to higher toxicity but high response rates.
Cilta-Cel Shows Promise in Earlier Lines of Treatment in Patients With Progressive Multiple Myeloma
Cohort A of the CARTITUDE-2 study is evaluating cilta-cel safety and efficacy in patients with multiple myeloma who received 1 to 3 prior lines of therapy.
Lete-Cel Exhibits Anti-Tumor Activity, Long Median PFS in Patients With Myxoid/Round Cell Liposarcoma
“Therapy was found to be safe and tolerable. This initial data formed the basis for further exploration that is currently ongoing in the IGNYTE-ESO study,” investigator Sandra P. D’Angelo, MD, tells CGTL.
Brexu-Cel Shows Efficacy in Mantle Cell Lymphoma in Real-World Setting
High response rates were seen in patients that would not meet ZUMA-2 eligibility criteria.
Axi-Cel Shows Favorable Outcomes in Large B-Cell Lymphoma Regardless of Race, Ethnicity
No differences were found in overall survival and progression free survival across races.
Allogeneic CAR T-Cell Therapy Well-Tolerated and Effective Across B-Cell Malignancies
A recent meta-analysis reviewed data across 146 patients in 9 clinical trials.
CAR T-Cell Therapy Yields High Response Rates in B-NHL
Relma-cel was previously approved in China in September 2021 for the treatment of B-cell non-Hodgkin lymphoma.
NK Cell Therapy Avelumab Combo Well Tolerated With Some Clinical Activity in Sarcoma
A phase 1 trial evaluated the combination in patients regardless of PD-L1 status and no differences were seen between those negative or positive.
Liso-Cel Yields High Response Rates and Positive PROs in LBCL
Treated patients had significant improvements in fatigue and lymphoma symptoms.
CAR T-Cell Therapy Demonstrates Feasibility in Resistant Prostate Cancer
The trial, sponsored by Mustang Bio, will continue to enroll patients and doses will be escalated to 300 million cells.
Memory T Cell CAR T Therapy Showcases Anti-Tumor Activity in Resistant Prostate Cancer
Interim data from the SPOTLIGHT study were presented at the ASCO GU Symposium.
TCR T-Cell Therapy to be Evaluated in Advanced Esophageal or EGJ Cancers
The SURPASS-2 trial will run parallel to the ongoing SURPASS trial.
HLA LOH Prevalent in GI Cancers, Identifies Future Study Participants
The BASECAMP-1 study is identifying patients for future use of Tmod CAR T-cell therapies.
Novel Chemo/NK Cell Therapy Combination Shows Efficacy in Pancreatic Cancer
Data from the phase 2 QUILT-88 study were presented at the 2022 ASCO GI symposium.
First In-Human Study Initiated for CAR Macrophage Cell Therapy for Solid Tumors
Carisma Therapeutics and Moderna are also collaborating to develop CAR-M cell therapies.
First Patient Dosed in CAR T-Cell Therapy/Pembrolizumab Trial for Colorectal Cancer
Further details on the KEYNOTE-B79 trial were presented at the 2022 ASCO GI Symposium.
Emerging Data in Diffuse Large B-Cell Lymphoma
Experts discussed data from trials in lymphoma presented at ASCO 2021.
Novel Treatments for Hematologic Malignancies: Julie Vose, MD
The professor of internal medicine in the Division of Oncology and Hematology at the University of Nebraska Medical Center discussed novel treatment options for patients with hematologic malignancies.
Benefits of CAR T Therapy in Follicular Lymphoma: Julie Vose, MD
The professor of internal medicine in the Division of Oncology and Hematology at the University of Nebraska Medical Center discussed the benefits of CAR T-cell for patients with follicular lymphoma.
